Citations

Showing 10 of 108104 citations.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider
Unger, Julia , Putrik, Polina , Buttgereit, Frank , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Dias, João Madruga , Falzon, Louise , Gossec, Laure , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Dejaco, Christian , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000756

10.1136/rmdopen-2018-000756 | PMID 30714580 Get It

Objective To summarise the available information on physician workforce modelling, to develop a rheumatology workforce prediction risk of bias tool and to apply it to existing studies in rheumatology. Methods A systematic literature review (SLR) was performed in key electronic databases (1946–2017) comprising an update of an SLR in rheumatology and a hierarchical SLR in other medical fields. Data on the type of workforce prediction models and the factors considered in the models were extracted. Key general as well as specific need/demand and supply factors for workforce calculation in rheumatology were identified. The workforce prediction risk of bias tool was developed and applied to existing workforce studies in rheumatology. Results In total, 14 studies in rheumatology and 10 studies in other medical fields were included. Studies used a variety of prediction models based on a heterogeneous set of need/demand and/or supply factors. Only two studies attempted empirical validation of the prediction quality of the model. Based on evidence and consensus, the newly developed risk of bias tool includes 21 factors (general, need/demand and supply). The majority of studies revealed high or moderate risk of bias for most of the factors. Conclusions The existing evidence on workforce prediction in rheumatology is scarce, heterogeneous and at moderate or high risk of bias. The new risk of bias tool should enable future evaluation of workforce prediction studies. This review informs the European League Against Rheumatism points to consider for the conduction of workforce requirement studies in rheumatology.
EULAR ‘points to consider’ for the conduction of workforce requirement studies in rheumatology
Dejaco, Christian , Putrik, Polina , Unger, Julia , Aletaha, Daniel , Bianchi, Gerolamo , Čikeš, Nada, Gossec, Laure , Dias, João Madruga , Matteson, Eric L. , Wiek, Dieter , Zink, A. , Buttgereit, Frank , Stamm, Tanja A , Dejaco, Christian , Gossec, Laure , Buttgereit, Frank , Bijlsma, J. W. J. , Boonen, Annelies E. R. C. H. , Finckh, Axel , Kvien, Tore Kristian , Sivera, Francisca , Szekanecz, Zoltán , Ramiro, Sofía

Mayo Clinic

RMD Open | December 6, 2018 | Volume: 4 | Issue: 2 | Pages: e000780

10.1136/rmdopen-2018-000780 | PMID 30714579 Get It

Objective Current methods used for forecasting workforce requirements in rheumatology are disparate, as are the parameters incorporated into workforce projection studies. The objective of these European League Against Rheumatism (EULAR points to consider (PTC) is to guide future workforce studies in adult rheumatology in order to produce valid and reliable manpower estimates. Methods The EULAR Standardised Operating Procedures were followed. A multidisciplinary task force with experts including patients with rheumatic diseases from 11 EULAR countries and the USA was assembled. A systematic literature review (SLR) was conducted to retrieve workforce models in rheumatology and other medical fields. PTC were based on expert opinion informed by the SLR, followed by group discussions with consensus obtained through informal voting. The level of agreement with the PTC was voted anonymously. Results A total of 10 PTC were formulated. The task force recommends models integrating supply (=workforce available in rheumatology), demand (=health services requested by the population) and need (=health services that are considered appropriate to serve the population). In general, projections of workforce requirements should consider all factors relevant for current and future workload in rheumatology inside and outside of direct patient care. Forecasts of workforce supply should consider demography and attrition of rheumatologists, as well as the effects of new developments in healthcare. Predictions of future need/demand should take demographic, sociocultural and epidemiological development of the population into account. Conclusion These EULAR-endorsed PTC will provide guidance on the methodology and the parameters to be applied in future national and international workforce requirement studies in rheumatology.
PACE Forward‐Making Pharmacogenomics Testing Available for Real‐Life Clinical Utility
Lazaridis, Konstantinos N.

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 6, 2018 | Volume: 105 | Issue: 1 | Pages: 42-44

10.1002/cpt.1274 | PMID 30520030 Get It

Radiation Therapy for Retroperitoneal Sarcomas: Influences of Histology, Grade, and Size
Leiting, Jennifer L. , Bergquist, John R. , Merrell, Kenneth W. , Folpe, Andrew L. , Robinson, Steven I. , Nagorney, David M. , Truty, Mark J. , Grotz, Travis E. , Robinson, Steven I , Grotz, Travis E , Leiting, Jennifer L , Bergquist, John R , Hernandez, Matthew C.

Mayo Clinic

Sarcoma | December 5, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-8

10.1155/2018/7972389 | PMID 30631245 Get It

Perioperative radiation therapy (RT) has been associated with reduced local recurrence in patients with retroperitoneal sarcomas (RPS); however, selection criteria remain unclear. We hypothesized that perioperative RT would improve survival in patients with RPS and would be associated with pathological factors. The National Cancer Database (NCDB) from 2004 to 2012 was reviewed for patients with nonmetastatic RPS undergoing curative intent resection. Tumor size was dichotomized at 15 cm based on 8th edition American Joint Committee on Cancer (AJCC) staging. Patients with the highest comorbidity score were excluded. Unadjusted Kaplan–Meier and adjusted Cox proportional hazards modeling analyzed overall survival (OS). Multivariable logistic regression modeled margin positivity. A total of 2,264 patients were included; 727 patients (32.1%) had perioperative radiation in whom 203 (9.0%) had radiation preoperatively. Median (IQR) RPS size was 17.5 [11.0–27.0] cm. Histopathology was high grade in 1048 patients (43.7%). Multivariable analysis revealed that perioperative radiation was independently associated with decreased mortality (HR 0.72, 95% confidence intervals (CIs) 0.62–0.84,p<0.001), and preoperative RT was associated with reduced margin positivity (HR 0.72, 95% CI 0.53–0.97,p=0.032). Stratified survival analysis showed that radiation was associated with prolonged median OS for RPS that were high-grade (64.3 vs. 43.6 months,p<0.001), less than 15 cm (104.1 vs. 84.2 months,p=0.007), and leiomyosarcomatous (104.8 vs. 61.8 months,p<0.001). Perioperative radiation is independently associated with decreased mortality in patients with high-grade, less than 15 cm, and leiomyosarcomatous tumors. Preoperative radiation is independently associated with margin-negative resection. These data support the selective use of perioperative radiation in the multidisciplinary management of RPS.
An Unusual Case of Metastatic Follicular Thyroid Cancer 40 Years after Initial Diagnosis
Menon, Lakshmi , Maraka, Spyridoula , Menon, Lakshmi Pakath , Maraka, Spyridoula

Mayo Clinic

Case Reports in Endocrinology | December 5, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-3

10.1155/2018/2019235 | PMID 30627457 Get It

Thyroid cancer recurrence can occur decades after initial diagnosis despite excellent response to therapy. Thyroid cancer recurrence is evaluated using serum thyroglobulin (Tg) and imaging studies including I-131 WBS and neck ultrasound. Limitations in Tg measurement and WBS may result in failure to detect recurrence. We report the case of a 63-year-old man who was noted to have rhonchi during a routine visit. He had a past history of follicular thyroid cancer that was diagnosed 40 years ago and treated with total thyroidectomy and radioactive iodine. He had excellent response to therapy with undetectable Tg levels, normal neck ultrasounds, and multiple negative whole body scans (WBS) due to which he was discharged from endocrinology clinic after 37 years of follow-up. Chest X-ray revealed a left lung mass with biopsy positive for thyroid cancer. Tg remained undetectable with negative anti-Tg antibody. Left pneumonectomy was done which revealed a mix of 70% differentiated thyroid cancer and 30% poorly differentiated/anaplastic thyroid cancer. He received two cycles of Doxorubicin and Paclitaxel. At 4 months follow-up after surgery, he had 3 subcentimeter nodules in his right lung. This case highlights that physical exam remains an essential tool to evaluate for recurrence. Since the lungs are the most common site of metastasis in follicular thyroid cancer, a chest X-ray may help detect metastasis that is missed on other modalities.
The mystery of assisted reproductive technologies
Enninga, Elizabeth Ann L. , Enninga, Elizabeth Ann L , Roberson, Elle C.

Mayo Clinic

Molecular Reproduction and Development | December 5, 2018 | Volume: 86 | Issue: 2 | Pages: 121-121

10.1002/mrd.23094 | PMID 30516870 Get It

Multimodal imaging in familial FTLD: phenoconversion and planning for the future
Rosen, Howard J. , Boeve, Bradley F.

Mayo Clinic

Brain | December 5, 2018 | Volume: 142 | Issue: 1 | Pages: 8-11

10.1093/brain/awy314 | PMID 30596906 Get It

Management of Sepsis in Patients With Cirrhosis: Current Evidence and Practical Approach
Simonetto, Douglas A. , Serafim, Laura Piccolo, Moraes, Alice Gallo de , Gajić, Ognjen, Kamath, Patrick S. , Piccolo Serafim, Laura, Gallo de Moraes, Alice , Simonetto, Douglas A , Gajic, Ognjen

Mayo Clinic

Hepatology | December 5, 2018 | Volume: 70 | Issue: 1 | Pages: 418-428

10.1002/hep.30412 | PMID 30516866 Get It

Sepsis in patients with cirrhosis is associated with high mortality. An impaired immune response accounts for the increased infection risk observed in these patients. Hemodynamic and systemic changes suggestive of sepsis may be observed in patients with cirrhosis in the absence of infection; therefore, diagnosis and treatment of sepsis may be delayed. The optimal management of the critically ill patient with sepsis and cirrhosis has not been well established and is generally extrapolated from consensus guidelines and expert recommendations made for management of patients without cirrhosis with sepsis. Despite the lack of strong evidence, we propose a contemporary pragmatic approach to sepsis management in patients with cirrhosis, including the choice of fluids, vasopressors, and antibiotics.
The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly‐annotated patients with primary myelofibrosis
Tefferi, Ayalew , Mudireddy, Mythri , Finke, Christy M. , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Mudireddy, Mythri , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 299-305

10.1002/ajh.25349 | PMID 30516848 Get It

Abstract JAK2 mutations in myeloproliferative neoplasms (MPNs) are associated with the germline GGCC (46/1) haplotype. In 2010, we reported an association between shortened survival in primary myelofibrosis (PMF) and nullizygosity for the JAK2 46/1 haplotype. In the current study, we have increased the number of informative cases from 130 to 414 (median age 63 years; 63% males), in order to revisit with the phenotypic and prognostic relevance of the JAK2 46/1 haplotype in PMF. JAK2 46/1 haplotype was documented in 69% of the study patients, including 25% in homozygous and 44% in heterozygous state. Driver mutation frequency in patients homozygous/heterozygous/nullizygous for the 46/1 haplotype was 78%/60%/56% JAK2, 10%/20%/18% type 1‐like CALR, 3%/2%/5% type 2‐like CALR, 4%/8%/7% MPL, and 6%/10%/14% triple‐negative (P = .02). In univariate analysis, nullizygosity for the JAK2 46/1 haplotype was associated with inferior overall survival (HR 1.5, 95% CI 1.1‐1.9), most pronounced in JAK2 (P <.001), as opposed to CALR/MPL mutated (P = .48) or triple‐negative cases (P = .27). Multivariable analysis that included karyotype, driver mutational status and high‐molecular risk mutations confirmed the independent prognostic contribution of nullizygosity for the 46/1 haplotype (P = .02; HR 1.4, 95% CI 1.1‐1.8). Nullizygosity for 46/1 also remained significant in the context of the genetically‐inspired GIPSS risk model (P = .04), but not in the context of the integrated genetics‐clinical MIPSS70+ version 2.0 model (P = .4). Leukemia‐free survival was not affected by the 46/1 haplotype (P = .6). The current study confirms the association of nullizygosity for the JAK2 GGCC (46/1) haplotype with inferior survival in JAK2‐mutated PMF.